Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
orlistat, naltrexone/bupropion and phentermine) have a limited role in the management of overweight/obesity in people with or at high risk of CVD due to their minimal impact on weight, unknown CVD benefits and poor tolerability
Oxidative stress biomarkers (F2-isoprostanes, malondialdehyde) have reached their new reduced steady state
Without formal approval and reimbursement pathways, most patients in the UK and US cannot access GLP-1 therapies for endometriosis through public healthcare systems or insurance coverage
However, if you prefer a different concentration, you can request a custom reconstitution volume and calculate your own unit measurements using the charts in this guide
[2] Here's what Medicare coverage for Foundayo looks like today: For weight loss: The Medicare GLP-1 Bridge (live since July 1, 2026) covers all Foundayo formulations at $50/month for eligible Part D beneficiaries (BMI-based criteria + prior authorization) Your standard Part D plan: Still excludes Foundayo for weight loss by statutethe Bridge is the pathway, not your plan's formulary No carve-out indication: Unlike Zepbound (covered under Part D for sleep apnea), Foundayo is weight-loss focusedso the $50 Bridge is essentially your only Medicare pathway Bottom line: Medicare beneficiaries now have a real weight-loss pathway for Foundayothe $50 Bridge, covering all formulations
